SLC5A2 and autosomal dominant polycystic kidney disease: Yet, major clinical trials investigating SGLT2 inhibitors in CKD, including DAPA-CKD [3] and EMPA-KIDNEY [4], specifically excluded ADPKD patients from their study populations.